Faculty Opinions recommendation of NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study.

SynopsisIn a double-blind, placebo-controlled study with co-dergocrine in the treatment of tardive dyskinesia in a group of elderly chronic psychiatric patients the reduction of dyskinetic scores in the group receiving active medication was slightly greater than that in the placebo group; however, this difference did not reach a level of statistical significance. It is suggested that further work could be undertaken with a longer period of treatment, and at a higher dosage level of co-dergocrine, in a younger patient sample.

Download Full-text

Vitamin E in the treatment of tardive dyskinesia: a double-blind placebo-controlled study

American Journal of Psychiatry ◽

10.1176/ajp.149.3.391 ◽

1992 ◽

Vol 149 (3) ◽

pp. 391-393 ◽

Cited By ~ 55

Keyword(s):

Vitamin E ◽

Tardive Dyskinesia ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1104665.560731 ◽

2008 ◽

Author(s):

Daniel Tarsy ◽

Codrin Lungu

Keyword(s):

Tardive Dyskinesia ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Oxypertine in Tardive Dyskinesia: An 8-week Controlled Study

The British Journal of Psychiatry ◽

10.1192/bjp.144.1.48 ◽

1984 ◽

Vol 144 (1) ◽

pp. 48-52 ◽

Cited By ~ 3

Author(s):

S. D. Soni ◽

H. L. Freeman ◽

E. M. Hussein

Keyword(s):

Tardive Dyskinesia ◽

Controlled Trial ◽

Chronic Schizophrenia ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo

SummaryIn a double-blind placebo controlled trial of oxypertine in the treatment of tardive dyskinesia, 33 patients with chronic schizophrenia received either oxypertine or placebo. At the end of eight weeks, the results showed that oxypertine was superior to placebo at a statistically significant level.

Download Full-text

Effect of Anticholinergics on Tardive Dyskinesia

The British Journal of Psychiatry ◽

10.1192/bjp.145.3.304 ◽

1984 ◽

Vol 145 (3) ◽

pp. 304-310 ◽

Cited By ~ 47

Author(s):

W. Greil ◽

H. Haag ◽

G. Rossnagl ◽

E. Rüther

Keyword(s):

Tardive Dyskinesia ◽

Rating Scales ◽

Term Treatment ◽

Controlled Study ◽

Anticholinergic Medication ◽

Double Blind ◽

Double Blind Placebo ◽

Long Term Treatment ◽

Schizophrenic Patients

SummaryIn a double-blind, placebo-controlled study, ten chronic schizophrenic patients with pronounced symptoms of tardive dyskinesia (TD) were withdrawn from anticholinergic medication. All patients had previously been under long-term treatment with neuroleptics and anticholinergics for at least two years. The rating-scales used were the AIMS, our own TD Scale, and the Simpson-Angus scale for extra-pyramidal side-effects. The severity of TD decreased significantly in nine patients within two weeks; this improvement, most pronounced in the oral region (P <.001), persisted during a six-week placebo period. There was a slight increase in parkinsonian symptoms (P <.05), which was not a prerequisite for improvement in TD. Hence, discontinuation of anticholinergic medication is a possible therapeutic approach in patients with TD.

Download Full-text